Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery

Pharmacology and Therapeutics

Volumn 126, Issue 2, 2010, Pages 109-118

  Murata, Mitsushige ^a   Tohyama, Shugo ^a   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Arrhythmia; Cardiomyocyte; Drug discovery; Embryonic stem cell; Induce pluripotent stem cell; Regenerative medicine

Indexed keywords

CALCIUM CHANNEL; KETOCONAZOLE; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE2; POTASSIUM CHANNEL KCNQ1; SODIUM CHANNEL NAV1.5; TERFENADINE; TRANSCRIPTION FACTOR SOX2;

CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CARCINOGENESIS; CARDIAC CHANNELOPATHY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; DRUG ANTAGONISM; DRUG SCREENING; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HEART MUSCLE CELL; HEART REPOLARIZATION; HIGH THROUGHPUT SCREENING; HUMAN; INNER CELL MASS; LONG QT SYNDROME; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QT INTERVAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION; TERATOMA; TORSADE DES POINTES;

ANIMALS; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; ELECTROPHYSIOLOGICAL PHENOMENA; HUMANS; MYOCYTES, CARDIAC; PHARMACEUTICAL PREPARATIONS; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE;

EID: 77951090909     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.01.010     Document Type: Review

References (122)

1. Adewumi O., Aflatoonian B., Ahrlund-Richter L., Amit M., Andrews P.W., Beighton G., et al. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 2007, 25:803-816.
2. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced Torsades de Pointes. Heart Rhythm 2005, 2:S9-15.
3. Aoi T., Yae K., Nakagawa M., Ichisaka T., Okita K., Takahashi K., et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008, 321:699-702.
4. Bass A.S., Tomaselli G., Bullingham R., Kinter L.B. Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. J Pharmacol Toxicol Methods 2005, 52:12-21.
5. Belardinelli L., Shryock J.C., Wu L., Song Y. Use of preclinical assays to predict risk of drug-induced Torsades de Pointes. Heart Rhythm 2005, 2:S16-22.
6. Boyer L.A., Lee T.I., Cole M.F., Johnstone S.E., Levine S.S., Zucker J.P., et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122:947-956.
7. Boyer L.A., Mathur D., Jaenisch R. Molecular control of pluripotency. Curr Opin Genet Dev 2006, 16:455-462.
8. Brambrink T., Foreman R., Welstead G.G., Lengner C.J., Wernig M., Suh H., et al. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2008, 2:151-159.
9. Burashnikov A., Antzelevitch C. Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. J Cardiovasc Electrophysiol 2002, 13:172-177.
10. Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. J Intern Med 2006, 259:70-80.
11. Caspi O., Itzhaki I., Arbel G., Kehat I., Gepstien A., Huber I., et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev. 2008, May 29 [Electronic publication ahead of print].
12. Cowan C.A., Atienza J., Melton D.A., Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005, 309:1369-1373.
13. Cui L., Johkura K., Takei S., Ogiwara N., Sasaki K. Structural differentiation, proliferation, and association of human embryonic stem cell-derived cardiomyocytes in vitro and in their extracardiac tissues. J Struct Biol 2007, 158:307-317.
14. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80:795-803.
15. Dell'Era P., Ronca R., Coco L., Nicoli S., Metra M., Presta M. Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. Circ Res 2003, 93:414-420.
16. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
17. Ducroq J., Printemps R., Guilbot S., Gardette J., Salvetat C., Le Grand M. AP experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies. J Pharmacol Toxicol Methods 2007, 56:159-170.
18. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., Thomson J.A., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
19. Esteban M.A., Xu J., Yang J., Peng M., Qin D., Li W., et al. Generation of induced pluripotent stem cell lines from Tibetan miniature pig. J Biol Chem 2009, 284:17634-17640.
20. Evans M.J., Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292:154-156.
21. Fermini B., Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2003, 2:439-447.
22. Finlayson K., Witchel H.J., McCulloch J., Sharkey J. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol 2004, 500:129-142.
23. Freund C., Ward-van Oostwaard D., Monshouwer-Kloots J., van den Brink S., van Rooijen M., Xu X., et al. Insulin redirects differentiation from cardiogenic mesoderm and endoderm to neuroectoderm in differentiating human embryonic stem cells. Stem Cells 2008, 26:724-733.
24. Gai H., Leung E.L., Costantino P.D., Aguila J.R., Nguyen D.M., Fink L.M., et al. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biol Int 2009, 33:1184-1193.
25. Hanna J., Wernig M., Markoulaki S., Sun C.W., Meissner A., Cassady J.P., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923.
26. Harding S.E., Ali N.N., Brito-Martins M., Gorelik J. The human embryonic stem cell-derived cardiomyocyte as a pharmacological model. Pharmacol Ther 2007, 113:341-353.
27. Hattori F., Chen H., Yamashita H., Tohyama S., Satoh Y.S., Yuasa S., et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods 2010, 7:61-66.
28. He J.Q., Ma Y., Lee Y., Thomson J.A., Kamp T.J. Human embryonic stem cells develop into multiple types of cardiac myocytes: AP characterization. Circ Res 2003, 93:32-39.
29. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008, 26:795-797.
30. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008, 26:1269-1275.
31. January C.T., Moscucci A. Cellular mechanisms of early afterdepolarizations. Ann N Y Acad Sci 1992, 644:23-32.
32. January C.T., Riddle J.M. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 1989, 64:977-990.
33. January C.T., Riddle J.M., Salata J.J. A model for early afterdepolarizations: induction with the Ca2+ channel agonist Bay K 8644. Circ Res 1988, 62:563-571.
34. Jiang J., Chan Y.S., Loh Y.H., Cai J., Tong G.Q., Lim C.A., et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol 2008, 10:353-360.
35. Joshi A., Dimino T., Vohra Y., Cui C., Yan G.X. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol 2004, 37(Suppl):7-14.
36. Judson R.L., Babiarz J.E., Venere M., Blelloch R. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol 2009, 27:459-461.
37. Kaneko T., Kojima K., Yasuda K. An on-chip cardiomyocyte cell network assay for stable drug screening regarding community effect of cell network size. Analyst 2007, 132:892-898.
38. Kannankeril P.J., Roden D.M. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007, 22:39-43.
39. Kawai T., Takahashi T., Esaki M., Ushikoshi H., Nagano S., Fujiwara H., et al. Efficient cardiomyogenic differentiation of embryonic stem cell by fibroblast growth factor 2 and bone morphogenetic protein 2. Circ J 2004, 68:691-702.
40. Kehat I., Kenyagin-Karsenti D., Snir M., Segev H., Amit M., Gepstein A., et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001, 108:407-414.
41. Kim J., Chu J., Shen X., Wang J., Orkin S.H. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008, 132:1049-1061.
42. Kimura A. Molecular etiology and pathogenesis of hereditary cardiomyopathy. Circ J 2008, 72(Suppl A):A38-48.
43. Klug M.G., Soonpaa M.H., Koh G.Y., Field L.J. Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. J Clin Invest 1996, 98:216-224.
44. Kojima K., Kaneko T., Yasuda K. A novel method of cultivating cardiac myocytes in agarose microchamber chips for studying cell synchronization. J Nanobiotechnology 2004, 2:9.
45. Kojima K., Kaneko T., Yasuda K. Role of the community effect of cardiomyocyte in the entrainment and reestablishment of stable beating rhythms. Biochem Biophys Res Commun 2006, 351:209-215.
46. Kojima K., Moriguchi H., Hattori A., Kaneko T., Yasuda K. Two-dimensional network formation of cardiac myocytes in agar microculture chip with 1480 nm infrared laser photo-thermal etching. Lab Chip 2003, 3:292-296.
47. Kojima S., Eguchi H., Ookawara T., Fujiwara N., Yasuda J., Nakagawa K., et al. Clostridium botulinum type A progenitor toxin binds to Intestine-407 cells via N-acetyllactosamine moiety. Biochem Biophys Res Commun 2005, 331:571-576.
48. Kwon C., Arnold J., Hsiao E.C., Taketo M.M., Conklin B.R., Srivastava D. Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. Proc Natl Acad Sci U S A 2007, 104:10894-10899.
49. Laflamme M.A., Chen K.Y., Naumova A.V., Muskheli V., Fugate J.A., Dupras S.K., et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007, 25:1015-1024.
50. Lankipalli R.S., Zhu T., Guo D., Yan G.X. Mechanisms underlying arrhythmogenesis in long QT syndrome. J Electrocardiol 2005, 38:69-73.
51. Lee G., Papapetrou E.P., Kim H., Chambers S.M., Tomishima M.J., Fasano C.A., et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009, 461:402-406.
52. Lev S., Kehat I., Gepstein L. Differentiation pathways in human embryonic stem cell-derived cardiomyocytes. Ann N Y Acad Sci 2005, 1047:50-65.
53. Li W., Wei W., Zhu S., Zhu J., Shi Y., Lin T., et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009, 4:16-19.
54. Lin S.L., Chang D.C., Chang-Lin S., Lin C.H., Wu D.T., Chen D.T., et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. Rna 2008, 14:2115-2124.
55. Loh Y.H., Wu Q., Chew J.L., Vega V.B., Zhang W., Chen X., et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006, 38:431-440.
56. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 2008, 105:2883-2888.
57. Marban E. Cardiac channelopathies. Nature 2002, 415:213-218.
58. Maron B.J., Towbin J.A., Thiene G., Antzelevitch C., Corrado D., Arnett D., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006, 113:1807-1816.
59. Marson A., Foreman R., Chevalier B., Bilodeau S., Kahn M., Young R.A., et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 2008, 3:132-135.
60. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 2004, 43:369-379.
61. Mauritz C., Schwanke K., Reppel M., Neef S., Katsirntaki K., Maier L.S., et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008, 118:507-517.
62. McDevitt T.C., Laflamme M.A., Murry C.E. Proliferation of cardiomyocytes derived from human embryonic stem cells is mediated via the IGF/PI 3-kinase/Akt signaling pathway. J Mol Cell Cardiol 2005, 39:865-873.
63. Moore J.C., Fu J., Chan Y.C., Lin D., Tran H., Tse H.F., et al. Distinct cardiogenic preferences of two human embryonic stem cell (hESC) lines are imprinted in their proteomes in the pluripotent state. Biochem Biophys Res Commun 2008, 372:553-558.
64. Moretti A., Bellin M., Jung C.B., Thies T.M., Takashima Y., Bernshausen A., et al. Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J. 2009, October 22 [Electronic publication ahead of print].
65. Muller M., Fleischmann B.K., Selbert S., Ji G.J., Endl E., Middeler G., et al. Selection of ventricular-like cardiomyocytes from ES cells in vitro. FASEB J 2000, 14:2540-2548.
66. Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., Hassink R., et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003, 107:2733-2740.
67. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008, 26:101-106.
68. Narazaki G., Uosaki H., Teranishi M., Okita K., Kim B., Matsuoka S., et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 2008, 118:498-506.
69. Nascone N., Mercola M. An inductive role for the endoderm in Xenopus cardiogenesis. Development 1995, 121:515-523.
70. Nemir M., Croquelois A., Pedrazzini T., Radtke F. Induction of cardiogenesis in embryonic stem cells via downregulation of Notch1 signaling. Circ Res 2006, 98:1471-1478.
71. Norstrom A., Akesson K., Hardarson T., Hamberger L., Bjorquist P., Sartipy P. Molecular and pharmacological properties of human embryonic stem cell-derived cardiomyocytes. Exp Biol Med (Maywood) 2006, 231:1753-1762.
72. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
73. Olson E.N. Development. The path to the heart and the road not taken. Science 2001, 291:2327-2328.
74. Osafune K., Caron L., Borowiak M., Martinez R.J., Fitz-Gerald C.S., Sato Y., et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 2008, 26:313-315.
75. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
76. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
77. Passier R., Oostwaard D.W., Snapper J., Kloots J., Hassink R.J., Kuijk E., et al. Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. Stem Cells 2005, 23:772-780.
78. Passier R., van Laake L.W., Mummery C.L. Stem-cell-based therapy and lessons from the heart. Nature 2008, 453:322-329.
79. Paulussen A.D., Gilissen R.A., Armstrong M., Doevendans P.A., Verhasselt P., Smeets H.J., et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004, 82:182-188.
80. Priori S.G., Aliot E., Blomstrom-Lundqvist C., Bossaert L., Breithardt G., Brugada P., et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001, 22:1374-1450.
81. Reppel M., Igelmund P., Egert U., Juchelka F., Hescheler J., Drobinskaya I. Effect of cardioactive drugs on AP generation and propagation in embryonic stem cell-derived cardiomyocytes. Cell Physiol Biochem 2007, 19:213-224.
82. Reubinoff B.E., Pera M.F., Fong C.Y., Trounson A., Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 2000, 18:399-404.
83. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 2004, 350:1013-1022.
84. Sartiani L., Bettiol E., Stillitano F., Mugelli A., Cerbai E., Jaconi M.E. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 2007, 25:1136-1144.
85. Satin J., Itzhaki I., Rapoport S., Schroder E.A., Izu L., Arbel G., et al. Calcium handling in human embryonic stem cell-derived cardiomyocytes. Stem Cells 2008, 26:1961-1972.
86. Satin J., Kehat I., Caspi O., Huber I., Arbel G., Itzhaki I., et al. Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J Physiol 2004, 559:479-496.
87. Schenke-Layland K., Rhodes K.E., Angelis E., Butylkova Y., Heydarkhan-Hagvall S., Gekas C., et al. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells 2008, 26:1537-1546.
88. Shantsila E., Watson T., Lip G.Y. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace 2007, 9(Suppl 4):iv37-iv44.
89. Shi Y., Do J.T., Desponts C., Hahm H.S., Scholer H.R., Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008, 2:525-528.
90. Snir M., Kehat I., Gepstein A., Coleman R., Itskovitz-Eldor J., Livne E., et al. Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. Am J Physiol Heart Circ Physiol 2003, 285:H2355-2363.
91. Snyders D.J. Structure and function of cardiac potassium channels. Cardiovasc Res 1999, 42:377-390.
92. Stadtfeld M., Maherali N., Breault D.T., Hochedlinger K. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008, 2:230-240.
93. Sumi T., Tsuneyoshi N., Nakatsuji N., Suemori H. Defining early lineage specification of human embryonic stem cells by the orchestrated balance of canonical Wnt/beta-catenin, Activin/Nodal and BMP signaling. Development 2008, 135:2969-2979.
94. Takahashi K., Okita K., Nakagawa M., Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007, 2:3081-3089.
95. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
96. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
97. Takahashi T., Lord B., Schulze P.C., Fryer R.M., Sarang S.S., Gullans S.R., et al. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation 2003, 107:1912-1916.
98. Tamargo J., Caballero R., Gomez R., Valenzuela C., Delpon E. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004, 62:9-33.
99. Tanaka T., Tohyama S., Murata M., Nomura F., Kaneko T., Chen H., et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 2009, 385:497-502.
100. Terami H., Hidaka K., Katsumata T., Iio A., Morisaki T. Wnt11 facilitates embryonic stem cell differentiation to Nkx2.5-positive cardiomyocytes. Biochem Biophys Res Commun 2004, 325:968-975.
101. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
102. Ueno S., Weidinger G., Osugi T., Kohn A.D., Golob J.L., Pabon L., et al. Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc Natl Acad Sci U S A 2007, 104:9685-9690.
103. Vijayaragavan K., Szabo E., Bosse M., Ramos-Mejia V., Moon R.T., Bhatia M. Noncanonical Wnt signaling orchestrates early developmental events toward hematopoietic cell fate from human embryonic stem cells. Cell Stem Cell 2009, 4:248-262.
104. Wakayama T., Hayashi Y., Ogura A. Participation of the female pronucleus derived from the second polar body in full embryonic development of mice. J Reprod Fertil 1997, 110:263-266.
105. Wang Q., Curran M.E., Splawski I., Burn T.C., Millholland J.M., VanRaay T.J., et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996, 12:17-23.
106. Wang Q., Shen J., Splawski I., Atkinson D., Li Z., Robinson J.L., et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995, 80:805-811.
107. Wilmut I., Schnieke A.E., McWhir J., Kind A.J., Campbell K.H. Viable offspring derived from fetal and adult mammalian cells. Nature 1997, 385:810-813.
108. Woltjen K., Michael I.P., Mohseni P., Desai R., Mileikovsky M., Hamalainen R., et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458:766-770.
109. Xu C., He J.Q., Kamp T.J., Police S., Hao X., O'Sullivan C., et al. Human embryonic stem cell-derived cardiomyocytes can be maintained in defined medium without serum. Stem Cells Dev 2006, 15:931-941.
110. Xu C., Police S., Rao N., Carpenter M.K. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res 2002, 91:501-508.
111. Xu Y., Huangfu H., Wang B., Cheng Y., Zhang Y. Application of SELDI-TOF-MS technology in study of laryngeal carcinoma biomarkers. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008, 22:820-823.
112. Yamashita J., Itoh H., Hirashima M., Ogawa M., Nishikawa S., Yurugi T., et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 2000, 408:92-96.
113. Yanagi K., Takano M., Narazaki G., Uosaki H., Hoshino T., Ishii T., et al. Hyperpolarization-activated cyclic nucleotide-gated channels and T-type calcium channels confer automaticity of embryonic stem cell-derived cardiomyocytes. Stem Cells 2007, 25:2712-2719.
114. Yokoo N., Baba S., Kaichi S., Niwa A., Mima T., Doi H., et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun 2009, 387:482-488.
115. Yu J., Hu K., Smuga-Otto K., Tian S., Stewart R., Slukvin I.I., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801.
116. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
117. Yuasa S., Itabashi Y., Koshimizu U., Tanaka T., Sugimura K., Kinoshita M., et al. Transient inhibition of BMP signaling by Noggin induces cardiomyocyte differentiation of mouse embryonic stem cells. Nat Biotechnol 2005, 23:607-611.
118. Zechnich A.D., Hedges J.R., Eiselt-Proteau D., Haxby D. Possible interactions with terfenadine or astemizole. West J Med 1994, 160:321-325.
119. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009, 104:e30-41.
120. Zhao J., Huangfu X., He Y., Yang X., Zhu Y. Simultaneous double-bundle anterior cruciate ligament and posterior cruciate ligament reconstruction with autogenous hamstring tendons. Arthroscopy 2008, 24:1205-1213.
121. Zhao Y., Yin X., Qin H., Zhu F., Liu H., Yang W., et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008, 3:475-479.
122. Zwi L., Caspi O., Arbel G., Huber I., Gepstein A., Park I.H., et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 2009, 120:1513-1523.